Asia Pacific has been the fastest growing region in multi-specific monoclonal antibody trials since 2018, with the region contributing to over 40% of the global trials, relatively higher than that of the US and Europe.
Novotech Publishes Multi-Specific Monoclonal Antibodies Global Clinical Trial Landscape Report
Singapore - Novotech, the leading Asia Pacific centred biotech CRO has published
Read more